Thy-1 (CD90) is an interacting partner for CD97 on activated endothelial cells

Journal of Immunology

Volumn 188, Issue 3, 2012, Pages 1442-1450

  Wandel, Elke ^a   Saalbach, Anja ^a   Sittig, Doreen ^a   Gebhardt, Carl ^a   Aust, Gabriela ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CD97 ANTIGEN; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; THY 1 ANTIGEN;

ABSCESS; ADULT; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL ADHESION; CELLULAR DISTRIBUTION; CHO CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE MIGRATION; MALE; MICROABSCESS; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; PSORIASIS; STABLE EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, THY-1; CASE-CONTROL STUDIES; CELL ADHESION; ENDOTHELIAL CELLS; FEMALE; HUMANS; LEUKOCYTE ROLLING; LEUKOCYTES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROTEIN BINDING; PSORIASIS;

EID: 84856564972     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003944     Document Type: Article

References (38)

1. Crawford, J. M., and R. W. Barton. 1986. Thy-1 glycoprotein: structure, distribution, and ontogeny. Lab. Invest. 54: 122-135. (Pubitemid 16086507)
2. Dalchau, R., A. S. Daar, and J. W. Fabre. 1989. The human Thy-1 molecule. Immunol. Ser. 45: 185-196.
3. Saalbach, A., G. Aust, U. F. Haustein, K. Herrmann, and U. Anderegg. 1997. The fibroblast-specific MAb AS02: a novel tool for detection and elimination of human fibroblasts. Cell Tissue Res. 290: 593-599. (Pubitemid 27522259)
4. Saalbach, A., U. F. Haustein, and U. Anderegg. 2000. A ligand of human thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated thy-1-positive microvascular endothelial cells and fibroblasts. J. Invest. Dermatol. 115: 882-888.
5. Wetzel, A., T. Chavakis, K. T. Preissner, M. Sticherling, U. F. Haustein, U. Anderegg, and A. Saalbach. 2004. Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J. Immunol. 172: 3850-3859. (Pubitemid 38337972)
6. Wetzel, A., T. Wetzig, U. F. Haustein, M. Sticherling, U. Anderegg, J. C. Simon, and A. Saalbach. 2006. Increased neutrophil adherence in psoriasis: role of the human endothelial cell receptor Thy-1 (CD90). J. Invest. Dermatol. 126: 441-452. (Pubitemid 43323182)
7. Bjarnadóttir, T. K., R. Fredriksson, P. J. Höglund, D. E. Gloriam, M. C. Lagerström, and H. B. Schiöth. 2004. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. Genomics 84: 23-33. (Pubitemid 38760127)
8. Eichler, W., G. Aust, and D. Hamann. 1994. Characterization of an early activation-dependent antigen on lymphocytes defined by the monoclonal antibody BL-Ac(F2). Scand. J. Immunol. 39: 111-115. (Pubitemid 24232906)
9. Lin, H. H., G. W. Chang, J. Q. Davies, M. Stacey, J. Harris, and S. Gordon. 2004. Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif. J. Biol. Chem. 279: 31823-31832. (Pubitemid 39037855)
10. Hamann, J., J. O. Wishaupt, R. A. van Lier, T. J. Smeets, F. C. Breedveld, and P. P. Tak. 1999. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 42: 650-658. (Pubitemid 29171984)
11. Lin, H. H., M. Stacey, J. Hamann, S. Gordon, and A. J. McKnight. 2000. Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97. Genomics 67: 188-200. (Pubitemid 30614587)
12. Kwakkenbos, M. J., G. W. Chang, H. H. Lin, W. Pouwels, E. C. de Jong, R. A. van Lier, S. Gordon, and J. Hamann. 2002. The human EGF-TM7 family member EMR2 is a heterodimeric receptor expressed on myeloid cells. J. Leukoc. Biol. 71: 854-862.
13. Galle, J., D. Sittig, I. Hanisch, M. Wobus, E. Wandel, M. Loeffler, and G. Aust. 2006. Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion. Am. J. Pathol. 169: 1802-1811. (Pubitemid 351182009)
14. Yona, S., H. H. Lin, P. Dri, J. Q. Davies, R. P. Hayhoe, S. M. Lewis, S. E. Heinsbroek, K. A. Brown, M. Perretti, J. Hamann, et al. 2008. Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB J. 22: 741-751. (Pubitemid 351348127)
15. Wobus, M., B. Vogel, E. Schmücking, J. Hamann, and G. Aust. 2004. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int. J. Cancer 112: 815-822. (Pubitemid 39435266)
16. Kwakkenbos, M. J., R. A. van Lier, and J. Hamann. 2002. Characterization of EGF-TM7 family members by novel monoclonal antibodies. In Leucocyte Typing VII. White Cell Differentiation Antigens. D. Mason, ed. Oxford University Press, Oxford, p. 381-383.
17. Stacey, M., G. W. Chang, J. Q. Davies, M. J. Kwakkenbos, R. D. Sanderson, J. Hamann, S. Gordon, and H. H. Lin. 2003. The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 102: 2916-2924. (Pubitemid 37248865)
18. Saalbach, A., A. Wetzel, U. F. Haustein, M. Sticherling, J. C. Simon, and U. Anderegg. 2005. Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 24: 4710-4720. (Pubitemid 41032607)
19. Hamann, J., B. Vogel, G. M. van Schijndel, and R. A. van Lier. 1996. The sevenspan transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J. Exp. Med. 184: 1185-1189. (Pubitemid 26313577)
20. Veninga, H., S. Becker, R. M. Hoek, M. Wobus, E. Wandel, J. van der Kaa, M. van der Valk, A. F. de Vos, H. Haase, B. Owens, et al. 2008. Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J. Immunol. 181: 6574-6583.
21. Saalbach, A., G. Hildebrandt, U. F. Haustein, and U. Anderegg. 2002. The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1- positive microvascular endothelial cells. Microvasc. Res. 64: 86-93. (Pubitemid 34713234)
22. Hamann, J., W. Eichler, D. Hamann, H. M. Kerstens, P. J. Poddighe, J. M. Hoovers, E. Hartmann, M. Strauss, and R. A. van Lier. 1995. Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J. Immunol. 155: 1942-1950.
23. Stacey, M., G. W. Chang, S. L. Sanos, L. R. Chittenden, L. Stubbs, S. Gordon, and H. H. Lin. 2002. EMR4, a novel epidermal growth factor (EGF)-TM7 molecule up-regulated in activated mouse macrophages, binds to a putative cellular ligand on B lymphoma cell line A20. J. Biol. Chem. 277: 29283-29293.
24. Hamann, J., C. Stortelers, E. Kiss-Toth, B. Vogel, W. Eichler, and R. A. van Lier. 1998. Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur. J. Immunol. 28: 1701-1707. (Pubitemid 28221175)
25. Venneker, G. T., P. K. Das, M. M. Meinardi, J. van Marle, H. A. van Veen, J. D. Bos, and S. S. Asghar. 1994. Glycosylphosphatidylinositol (GPI)-anchored membrane proteins are constitutively down-regulated in psoriatic skin. J. Pathol. 172: 189-197. (Pubitemid 24098671)
26. Boulday, G., J. Hamann, J. P. Soulillou, and B. Charreau. 2002. CD97-decay-accelerating factor interaction is not involved in leukocyte adhesion to endothelial cells. Transplantation 73: 429-436. (Pubitemid 34174294)
27. Wang, T., Y. Ward, L. Tian, R. Lake, L. Guedez, W. G. Stetler-Stevenson, and K. Kelly. 2005. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105: 2836-2844. (Pubitemid 40446277)
28. McInnes, I. B., G. G. Illei, C. L. Danning, C. H. Yarboro, M. Crane, T. Kuroiwa, R. Schlimgen, E. Lee, B. Foster, D. Flemming, et al. 2001. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J. Immunol. 167: 4075-4082. (Pubitemid 32910855)
29. Schubert, K., T. Polte, U. Bönisch, S. Schader, R. Holtappels, G. Hildebrandt, J. Lehmann, J. C. Simon, U. Anderegg, and A. Saalbach. 2011. Thy-1 (CD90) regulates the extravasation of leukocytes during inflammation. Eur. J. Immunol. 41: 645-656.
30. Bradley, J. E., G. Ramirez, and J. S. Hagood. 2009. Roles and regulation of Thy-1, a context-dependent modulator of cell phenotype. Biofactors 35: 258-265.
31. Ishizu, A., H. Ishikura, Y. Nakamaru, E. Takeuchi, C. Kimura, T. Koike, and T. Yoshiki. 1995. Thy-1 induced on rat endothelium regulates vascular permeability at sites of inflammation. Int. Immunol. 7: 1939-1947. (Pubitemid 26003700)
32. Ishizu, A., H. Ishikura, Y. Nakamaru, K. Kikuchi, T. Koike, and T. Yoshiki. 1997. Interleukin-1alpha regulates Thy-1 expression on rat vascular endothelial cells. Microvasc. Res. 53: 73-78. (Pubitemid 27204884)
33. Haeryfar, S. M., and D. W. Hoskin. 2004. Thy-1: more than a mouse pan-T cell marker. J. Immunol. 173: 3581-3588. (Pubitemid 39280715)
34. Kwakkenbos, M. J., W. Pouwels, M. Matmati, M. Stacey, H. H. Lin, S. Gordon, R. A. van Lier, and J. Hamann. 2005. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J. Leukoc. Biol. 77: 112-119. (Pubitemid 40310699)
35. Saalbach, A., T. Wetzig, U. F. Haustein, and U. Anderegg. 1999. Detection of human soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum. Cell Tissue Res. 298: 307-315. (Pubitemid 29512082)
36. Leemans, J. C., A. A. te Velde, S. Florquin, R. J. Bennink, K. de Bruin, R. A. van Lier, T. van der Poll, and J. Hamann. 2004. The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J. Immunol. 172: 1125-1131. (Pubitemid 38120256)
37. de Groot, D. M., G. Vogel, J. Dulos, L. Teeuwen, K. Stebbins, J. Hamann, B. M. Owens, H. van Eenennaam, E. Bos, and A. M. Boots. 2009. Therapeutic antibody targeting of CD97 in experimental arthritis: the role of antigen expression, shedding, and internalization on the pharmacokinetics of anti-CD97 monoclonal antibody 1B2. J. Immunol. 183: 4127-4134.
38. Wang, T., L. Tian, M. Haino, J. L. Gao, R. Lake, Y.Ward, H.Wang, U. Siebenlist, P. M. Murphy, and K. Kelly. 2007. Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect. Immun. 75: 1144-1153. (Pubitemid 46385805)